Abstract:e16246 Background: The COVID-19 pandemic has posed challenges to healthcare systems, notably impacting cancer care. For patients with Hepatobiliary and Pancreatic Cancer, there has been a reported decline in median survival. The etiology of this decline, whether it is attributed to an escalation in disease severity or to delays in diagnosis and treatment remains unclear. Methods: This retrospective study analyzed the National Cancer Database (NCDB 2004-2020) data from 2018 to 2020. We compared time from diagnosis to initial treatment, AJCC (2017) TNM clinical stage distribution, and pathological variables suggestive of tumor aggression between the pre-pandemic and pandemic periods, as well as within COVID-19 positive (C19+) and negative (C19-) patients. Results: The study included 17,429 liver cancer (LC), 37,185 pancreatic cancer (PC), 1,684 gallbladder cancer (GC), and 3,651 intrahepatic biliary cancer (IBC) patient’s pre-pandemic, and 14,420 LC and 35,456 PC, 1,457 GC, and 3,792 IBC patients during the pandemic. The time to initial treatment did not significantly differ in the before and during the pandemic groups for all types of cancer. However, for GC, there was a significant increase in days to definitive surgery during the pandemic 54 ±73 days compared to pre-pandemic 28±53 days (p < 0.01). There was also a notable increase in the time to initial treatment and definitive surgery for pancreatic cancer in C19+ patients (46±51, 118±104 days) compared to C19- patients (35±37, 97±89 respectively) (p < 0.01). For LC and GC, there was a significant increase in late-stage diagnoses during the pandemic period. LC (stage III: 23.67% and stage IV: 21.10%) compared to pre-pandemic (stage III: 22.71% and stage IV: 19.02%, p < 0.01). GC (stage IV: 77.0%) compared to pre-pandemic (stage IV: 71.85%, p < 0.01). Lympho-vascular invasion rates and node positivity ratios in HC, GC, and IBC patients remained unchanged. For PC there was no change in late stage distribution and IBC there were no significant differences in overall stage distribution or lympho-vascular invasion rates. However, a significant increase in node positive/node harvested ratio was observed in stage III C19+ PC patients (0.308±0.322) compared to C19- (0.134±0.181, p < 0.01). Conclusions: Cancer screening delays during the pandemic led to an increase in late-stage diagnoses for LC and GC but stage distributions for PC and IBC were largely unchanged. However, the pandemic's impact was subtly observed in the form of increased node positivity in stage III C19+ pancreatic cancer patients possibly due to their delay in initial treatment and surgery. There was also an increase in time to definitive surgery in gallbladder cancer. These findings underscore the importance of maintaining robust cancer care pathways, particularly for high-risk groups, to prevent adverse stage migration and ensure timely management, even in the face of global health emergencies.

The Impact of Omicron Pandemic and COVID‐19 Vaccination on the Pancreatic Adenocarcinoma Patients

Safety and Current Status of the COVID-19 Vaccine among Patients with Breast Cancer: A Cross-Sectional Study from China

Advanced pancreatic cancer outcomes and the impact of COVID-19 pandemic: The experience of an academic cancer center.

Suboptimal Declines and Delays in Early Breast Cancer Treatment after COVID-19 Quarantine Restrictions in China: A National Survey of 8397 Patients in the First Quarter of 2020.

Patients with advanced pancreatic and biliary cancer appear vulnerable to SARS-CoV-2 Omicron variant: An observational study during the COVID-19 outbreak in Shanghai

Impact of the COVID-19 Epidemic on a Pan-Asian Academic Oncology Clinical Trial

The impact of SARS-CoV2 Omicron variants epidemic on patients with cancer in China.

The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai

Clinical characteristics and prognostic factors of COVID-19 infection among cancer patients during the December 2022 - February 2023 Omicron variant outbreak

COVID-19 in cancer patients: The impact of vaccination on outcomes early in the pandemic

When Cancer Patients Encountered COVID-19: Clinical Characteristics and Outcome in China

Impact of the Coronavirus disease pandemic on early breast cancer

[Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer During Epidemic Novel Coronavirus Pneumonia].

Impact of the COVID‐19 pandemic on short‐term outcomes after pancreaticoduodenectomy for pancreatic cancer: A retrospective study from the Japanese National Clinical Database, 2018–2021

Impact of antitumor regimens on the outcomes of cancer patients with COVID-19: a pooled analysis

Impact of the Coronavirus Disease 2019 pandemic on neoadjuvant chemotherapy use in patients diagnosed with epithelial type ovarian cancer

Comment on "Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression"

Real-world Scenario of Patients with Lung Cancer Amid the COVID-19 Pandemic in China

Impact of the COVID-19 pandemic on disease progression in patients with hepatobiliary and pancreatic cancer.

Impact of the COVID‐19 pandemic on cancer healthcare utilization in southwestern China on March 2021

The Impact of the COVID-19 Pandemic on Multidisciplinary Clinics: A High-Volume Pancreatic Cancer Center Experience